Course Typologies, Treatment Principles, and Research Concepts

In order to explore the mechanisms of illness course and outcome and to improve treatment in schizophrenia and affective disorders, a theoretical framework as provided by the biopsychosocial concept, e. g. the vulnerability-stress-coping model, has been applied. To develop a coherent and valid research strategy, however, respective model components have to be translated into neuroscience concepts and operationalized accordingly. Course characteristics (typologies, markers), course influences (determinants, triggers, modifiers) and course predictors are discussed from a theoretical perspective. Building on this discussion, an integrative concept of illness course and course mechanisms is proposed. Finally, further research recommendations are given. Future research should elaborate on the neurobiological characteristics of course and outcome in methodologically adequate prospective interventional long-term studies.

References

• 1 American Psychiatric A ssociation. Practice guidelines for the treatment of patients with schizophrenia. Washington, DC; 1997
• 2 Awad A G. Prediction research of neuroleptic treatment outcome in schizophrenia - state of the art. In Gaebel W, Awad AG, editors Prediction of neuroleptic treatment outcome in schizophrenia. Concepts and methods. Wien; Springer 1994: p 1-14
• 3 Berrios G E. The history of descriptive psychopathology. In Mezzich JE, Jorge MR, Salloum IM, editors Psychiatric epidemiology. Assessment concepts and methods. Baltimore; Hopkins University Press 1994: p 47-68
• 4 Bleuler E. Dementia praecox oder Gruppe der Schizophrenien. In Aschaffenburg G, editor Handbuch der Psychiatrie. Leipzig; Deuticke 1911
• 5 Bleuler M. The schizophrenic disorders: long-term patient and family studies. Translated by Clemens SM New Haven, Conn; Yale University Press 1978
• 6 Breier A, Schreiber J L, Dyer J, Pickar D. Course of illness and predictors of outcome in chronic schizophrenia: implications for pathophysiology.  Br J Psychiatry. 1992;  (Suppl 18) 38-43
• 7 Detre T, McDonald M C. Managed care and the future of psychiatry.  Arch Gen Psychiatry. 1997;  54 201-204
• 8 Engel G L. The clinical application of the biopsychosocial model.  Am J Psychiatry. 1980;  137 535-544
• 9 Frank E, Prien R F, Jarrett R B, Keller M B, Kupfer D J, Lavori P W, Rush A J, Weissman M M. Conceptualization and rational for consensus definitions of terms in major depressive disorders. Remission, recovery, relapse, and recurrence.  Arch Gen Psychiatry. 1991;  48 851-855
• 10 Gaebel W. Prediction research of outcome in neuroleptic treatment - definitions and concepts. In Gaebel W, Awad AG, editors Prediction of neuroleptic treatment outcome in schizophrenia. Concepts and methods. Wien; Springer 1994: 15-26
• 11 Gaebel W. Illness theory and identity of psychiatry.  Nervenarzt. 2001;  72 329 -330
• 12 Gaebel W, Awad A G. Prediction of neuroleptic treatment outcome in schizophrenia. Wien; Springer 1994
• 13 Gaebel W, Frommann N. Long-term course in schizophrenia: concepts, methods and research strategies.  Acta Psychiatr Scand. 2000;  102 (Suppl 407) 49-53
• 14 Gaebel W, Jänner M, Frommann N, Pietzcker A, Kopcke W, Linden M, Müller P, Müller-Spahn F, Tegeler J. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies.  Schizophr Res. 2002;  53 145-159
• 15 Gaebel W, Pietzker A, Ulrich G, Schley J, Müller-Oerlinghausen B. Predictors of neuroleptic treatment response in acute schizophrenia: results of a treatment study with perazine.  Pharmacopsychiatry. 1988;  21 384-386
• 16 Goodman A. Organic unity theory: the mind-body problem revisited.  Am J Psychiatry. 1991;  148 553-563
• 17 Gottesman I I, McGuffin P, Farmer A E. Clinical genetics as clues to the genetics of schizophrenia.  Schizophr Bull. 1987;  13 23-47
• 18 Hegarty J D, Baldessarini R J, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature.  Am J Psychiatry. 1994;  151 1409-1416
• 19 Herz M I, Lamberti J S. Prodromal symptoms and relapse prevention in schizophrenia.  Schizophr Bull. 1995;  21 541-551
• 20 Hogarty G E, Goldberg S C, Collaborative Study G roup. Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates.  Arch Gen Psychiatry. 1973;  28 54-64
• 21 Huber G, Gross G, Schüttler R. A long-term follow-up study of schizophrenia: psychiatric course of illness and prognosis.  Acta Psychiatr Scand. 1975;  52 49-57
• 22 Kendler K S. A Psychiatric dialogue on the mind-body problem.  Am J Psychiatry. 2001;  158 989-1000
• 23 Klein D. Harmful dysfunction, disorder, disease, illness and evolution.  J Abnormal Psychol. 1999;  108 421-429
• 24 Kraemer H C, Kazdin A E, Offord D R, Kessler R C, Jensen P S, Kupfer D J. Coming to terms with the terms of risk.  Arch Gen Psychiatry. 1997;  54 337-343
• 25 Larsen T K, Friis S, Haahr U, Joa I, Johannessen J O, Melle I, Opjordsmoen S, Simonsen E, Vaglum P. Early detection and intervention in first-episode schizophrenia: a critical review.  Acta Psychiatr Scand. 2001;  103 323-334
• 26 Lehman A F. Evaluating outcomes of treatments for persons with psychotic disorders.  J Clin Psychiatry. 1996;  57 (Suppl 11) 61-67
• 27 Lewis A. The state of psychiatry. New York; The science house 1967
• 28 Lieberman J A, Kane J M, Sarantakos S, Gadaleta D, Woerner M, Alvir M, Ramos-Lorenzi J. Prediction of relapse in schizophrenia.  Arch Gen Psychiatry. 1987;  44 597-603
• 29 Lieberman J A, Sheitman B B, Kinon B J. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity.  Neuropsychopharmacol. 1997;  17 205-229
• 30 Lieberman J A, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J. The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches.  Society of Biological Psychiatry. 2001;  50 884-897
• 31 Lilienfeld S, Marino L. Mental disorder as a Roschian concept: a critique of Wakefield’s ”harmful dysfunction” analysis.  J Abnormal Psy . 1995;  104 411-420
• 32 Linszen D, Dingemans P, Lenior M. Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications.  Schizophr Res. 2001;  51 55-61
• 33 Marengo J. Classifying the courses of schizophrenia.  Schizophr Bull. 1994;  20 519-536
• 34 May P RA. Predicting individual responses to drug treatment in schizophrenia: A test dose model.  J Nerv Ment Dis. 1976;  162 177-183
• 35 McGorry P D, Yung A R, Phillips L J, Yuen H P, Francey S, Cosgrave E M, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.  Arch Gen Psychiatry. 2002;  59 921-928
• 36 Mrazek P J, Haggarty R J. Committee on prevention of mental disorders. Washington DC; National Academy Press 1994
• 37 Nuechterlein K H. Vulnerability models for schizophrenia: State of the art. In Häfner HG, Janzarik W, editors Search for the causes of schizophrenia. Berlin; Springer 1987: pp 297-316
• 38 Piaget J. The psychology of intelligence. In Piaget J, editor The psychology of intelligence. London; Routledge & Kegan Paul 1992
• 39 Post R M. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder.  Am J Psychiatry. 1992;  149 999-1010
• 40 Riecher-Rossler A, Rossler W. The course of schizophrenic psychoses: what do we really know? A selective review from an epidemiological perspective.  Eur Arch Psychiatry Clin Neurosci. 1998;  248 189-202
• 41 Strauss J S. Mediating processes in schizophrenia. Towards a new dynamic psychiatry.  Br J Psychiatry. 1989;  155 22-28
• 42 Van Os J, Marcelis M. The ecogenetics of schizophrenia: a review.  Schizophr Res. 1998;  32 127-135
• 43 Van Praag H. Over the mainstream: diagnostic requirements for biological psychiatric research.  Psychiatry Res. 1997;  72 201-212
• 44 Van Praag H. Nosologomania: a disorder of psychiatry.  World J Biol Psychiatry. 2000;  1 151-158
• 45 Wakefield J. Evolutionary versus prototype analyses of the concept of disorder.  J Abnorm Psychol. 1999;  108 374-399
• 46 Warner R. The prevention of schizophrenia: what interventions are safe and effective?.  Schizophr Bull. 2001;  27 551-562
• 47 Watt D C, Katz K, Shepherd M. The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment.  Psychol Med. 1983;  13 663-670
• 48 Wölwer W, Buchkremer G R N, Häfner H G W, Klosterkötter J, Maier W, Möller H -J, Gaebel W. German Research Network on Schizophrenia.  Eur Arch Psychiatry Clin Neurosci. 2003;  253 321-329
• 49 Wyatt R J, Damiani L M, Henter I D. First-episode schizophrenia. Early intervention and medication discontinuation in the context of course and treatment.  Br J Psychiatry. 1998;  172 (Suppl) 77-83